[Towards the use of intravenous apoptotic leukocyte infusion as a cell-based therapy approach?].
In the past few years, significant advances have been performed in the field of cell-based therapies. This concerns mainly regenerative medicine with the use of stem cells, as well as the modulation of immune responses. In order to modulate allogeneic immune responses after transplantation, we have developed a cell therapy approach based on the immunomodulatory properties of intravenous donor apoptotic cell infusion. In allogeneic hematopoietic cell transplantation settings, we reported that intravenous apoptotic leukocyte infusion, simultaneously to allogeneic bone marrow grafts, favors hematopoietic engraftment, prevents alloimmunization and delays graft-versus-host disease. Here, we review the different factors and cells implicated in the immunomodulatory properties of apoptotic cells. Then, we discuss the potential significance of such observations in transfusion practice.
Inserm, UMR 645, EFS Bourgogne Franche-Comté, université de Franche-Comté, IFR 133 BP 1937, 1, boulevard A.-Fleming, 25020 Besançon cedex, France. philippe.saas@efs.sante.fr
P
P
Saas
F
F
Bonnefoy
F
F
Kleinclauss
Y
Y
Sun
P
P
Tiberghien
B
B
Gaugler
S
S
Perruche
D017209:Apoptosis; D001803:Blood Transfusion; D016026:Bone Marrow Transplantation / Q000379:methods; D016207:Cytokines / Q000502:physiology; D006086:Graft vs Host Disease / Q000517:prevention & control; D018380:Hematopoietic Stem Cell Transplantation / Q000379:methods; D006801:Humans; D007165:Immunosuppression Therapy / Q000379:methods; D007262:Infusions, Intravenous; D017708:Leukocyte Transfusion; D007962:Leukocytes / Q000166:cytology / Q000276:immunology*; D014184:Transplantation, Homologous / Q000009:adverse effects
D016207:Cytokines